Loading...
Generating destination analysis
Catalyst Play
Featured in “Three Gene-Editing Stocks to Own Before Biotech's Fall 2026 Catalyst Wave”
Fall '26 Readouts
CRISPR Therapeutics already made history with Casgevy, the first approved CRISPR therapy, and is pushing deeper into in-vivo editing and oncology. In a catalyst-dense autumn, the pioneer with an approved product and the broadest pipeline is where generalist money re-enters gene editing first.
The catalyst: The back half of 2026 is one of the most catalyst-dense stretches biotech has seen in years. The ESMO oncology congress and the ASH hematology meeting both land in the autumn, and the FDA's decision calendar is stacked — including a closely watched November 14 PDUFA date for ivonescimab in lung cancer. Clusters like this drive sector-wide risk-on, and capital flows first to the platforms with the deepest pipelines and clearest readouts. These three sit at the center of genetic medicine.
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Key Numbers
Market Cap
$5B
P/E
N/A
Revenue Growth
+350.0%
Gross Margin
N/A
ROE
N/A
About CRISPR Therapeutics
Listed on the NASDAQ, CRISPR Therapeutics operates as a small-cap player in the biotech sector, offering investors focused access to biotech and genomics growth drivers. Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease. With a $5B market capitalization and no current profitability, the business is characterized by exceptional revenue growth, reporting +350% revenue change year-over-year.
Expert Coverage
Unlock Full CRSP Analysis
Expert analysis and coverage for CRISPR Therapeutics
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-08-09
More in Biotech & Genomics
LLY
Eli Lilly and Company
91
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65DXCM
DexCom Inc.
90
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55REGN
Regeneron Pharmaceuticals
88
True North
Pure Play
Biotech powerhouse with strong antibody pipeline and Dupixent franchise.
NASDAQ
MCap $100BRev +7%P/E 22ALNY
Alnylam Pharmaceuticals
88
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%